# Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors

> **NCT07337460** · PHASE2 · RECRUITING · sponsor: **Northern Jiangsu People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Icaritin Soft Capsules and mFOLFOX ：Oxaliplatin,leucovorin calcium,5-fluorouracil

## Key facts

- **NCT ID:** NCT07337460
- **Lead sponsor:** Northern Jiangsu People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07337460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07337460, "Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07337460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*